{"name": "Ensemble Discovery",
 "permalink": "ensemble-discovery",
 "crunchbase_url": "http://www.crunchbase.com/company/ensemble-discovery",
 "homepage_url": "http://www.ensemblediscovery.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@ensemblediscovery.com",
 "phone_number": "617-492-6977",
 "description": "",
 "created_at": "Sat Mar 13 11:38:10 UTC 2010",
 "updated_at": "Sat Mar 13 11:51:11 UTC 2010",
 "overview": "\u003Cp\u003EEnsemble Discovery is developing a new class of therapeutics - the Ensemblins\u00e2\u201e\u00a2, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistry\u00e2\u201e\u00a2 (DPC\u00e2\u201e\u00a2) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       34],
      "assets/images/resized/0008/0213/80213v1-max-150x150.jpg"],
     [[250,
       57],
      "assets/images/resized/0008/0213/80213v1-max-250x250.jpg"],
     [[252,
       58],
      "assets/images/resized/0008/0213/80213v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "SAB member",
    "person":
     {"first_name": "Mark",
      "last_name": "Murcko",
      "permalink": "mark-murcko",
      "image":
       {"available_sizes":
         [[[150,
            135],
           "assets/images/resized/0027/4281/274281v1-max-150x150.jpg"],
          [[250,
            225],
           "assets/images/resized/0027/4281/274281v1-max-250x250.jpg"],
          [[450,
            405],
           "assets/images/resized/0027/4281/274281v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "CTO",
    "person":
     {"first_name": "James",
      "last_name": "M. Coull",
      "permalink": "james-m-coull",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7896/267896v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7896/267896v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7896/267896v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$15M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.ensemblediscovery.com/news/pr051204.pdf",
    "source_description": "ENSEMBLE DISCOVERY CORPORATION ANNOUNCES $15M SERIES A PREFERRED FINANCING",
    "raised_amount": 15000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2004,
    "funded_month": 5,
    "funded_day": 12,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Flagship Ventures",
         "permalink": "flagship-ventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0002/8188/28188v4-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0002/8188/28188v4-max-250x250.png"],
             [[323,
               74],
              "assets/images/resized/0002/8188/28188v4-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "ARCH Venture Partners",
         "permalink": "arch-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0003/6165/36165v2-max-150x150.png"],
             [[250,
               51],
              "assets/images/resized/0003/6165/36165v2-max-250x250.png"],
             [[300,
               62],
              "assets/images/resized/0003/6165/36165v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Oxford Bioscience Partners",
         "permalink": "oxford-bioscience-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0005/5118/55118v1-max-150x150.jpg"],
             [[250,
               61],
              "assets/images/resized/0005/5118/55118v1-max-250x250.jpg"],
             [[408,
               100],
              "assets/images/resized/0005/5118/55118v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "99 Erie Street ",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        124],
       "assets/images/resized/0008/0214/80214v1-max-150x150.jpg"],
      [[250,
        206],
       "assets/images/resized/0008/0214/80214v1-max-250x250.jpg"],
      [[450,
        372],
       "assets/images/resized/0008/0214/80214v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}